Figure 1.

Possible sites targeting host factors as a novel antiviral treatment. (1) Inhibition of HCV entry by anti-receptor antibodies; (2) Interference with the host metabolic factor involved in HCV replication; (3) Modulation of nuclear receptors involved in HCV replication; (4) Inhibition of HCV release. LDL-R: Low density lipoprotein receptor; HDL: High density lipoprotein; VLDL: Very low density lipoprotein; SRB-1: Scavenger receptor B1; FXR: Farnesoid X receptor; ER: Estrogen receptors; MTP: Microsomal triglyceride protein; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A.